BRASÍLIA (Reuters) – Brazil’s Butantan institute could supply at least 40 million doses of its own COVID-19 vaccine called Butanvac in the fourth quarter of 2021, said Director Dimas Covas on Thursday.
Speaking before a Senate panel investigating the federal government’s handling of the pandemic, Covas said clinical trials of the new vaccine can be concluded quickly, though they still need to be authorized by Brazilian health regulator Anvisa.
(Reporting by Maria Carolina Marcello; Writing by Ana Mano)
